Equillium wins Australian regulatory clearance for EQ504 Phase 1 trial
Bitget2026/10/05 20:06Equillium secured Australian TGA clearance under the CTN scheme to start a first-in-human Phase 1 trial of EQ504. HREC approval received. First dosing expected by early November 2026. Topline Phase 1 data projected about six months later. Program supports a potential ulcerative colitis proof-of-concept study in the second half of 2027, pending Phase 1 results. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Equillium Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610051605PRIMZONEFULLFEED9839913) on October 05, 2026, and is solely responsible for the information contained therein.
- Equillium secured Australian TGA clearance under the CTN scheme to start a first-in-human Phase 1 trial of EQ504.
- HREC approval received. First dosing expected by early November 2026. Topline Phase 1 data projected about six months later.
- Program supports a potential ulcerative colitis proof-of-concept study in the second half of 2027, pending Phase 1 results.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Copper prices approach historic highs! UBS remains bullish: "Still most optimistic"
A COVID Vaccine Stock on the S&P 500 Is Up 600% This Year
The number of stablecoin holders on the Solana chain has surpassed 14 million.
Cathie Wood’s ARK Sells Bitcoin ETF, SpaceX and Robinhood Shares in Portfolio Shift
Crypto prices
More
